Pacific Biosciences Of California (PACB) FCF Margin Growth (1y) (2011 - 2026)
Pacific Biosciences Of California (PACB) FCF Margin Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 194.00 |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 66.00 |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -192.00 |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 119.00 |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 1,788.00 |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -395.00 |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 112.00 |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -505.00 |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -473.00 |
| 10 | Pacific Biosciences Of California | 381.79 Mn | 144.92 Mn | 12.64 Mn | -1,995.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,995.00 |
| Mar 31, 2026 | -607.00 |
| Dec 31, 2025 | 3,762.00 |
| Sep 30, 2025 | 6,334.00 |
| Jun 30, 2025 | 7,953.00 |
| Mar 31, 2025 | 8,268.00 |
| Dec 31, 2024 | 1,984.00 |
| Sep 30, 2024 | 675.00 |
| Jun 30, 2024 | -6,227.00 |
| Mar 31, 2024 | 4,799.00 |
| Dec 31, 2023 | 13,725.00 |
| Sep 30, 2023 | 8,958.00 |
| Jun 30, 2023 | 8,958.00 |
| Mar 31, 2023 | -379.00 |
| Dec 31, 2022 | -14,343.00 |
| Jun 30, 2022 | -12,563.00 |
| Mar 31, 2022 | -16,814.00 |
| Dec 31, 2021 | -4,311.00 |
| Jun 30, 2021 | 8,472.00 |
| Mar 31, 2021 | -56,347.00 |